Infertility is when a couple of reproductive age is unable to conceive after a year or more of regular unprotected intercourse.

It can be primary if no pregnancy has ever occurred or secondary if pregnancy has occurred irrespective of the outcome.

Ovulation induction is part of patient's management which aims to achieve development of a single follicle & subsequent ovulation in woman w/ anovulation.

Differential Diagnosis

Impaired fertility caused by other endocrine dysfunctions:

  • Menstrual disorders and infertility can also be manifestations of underlying endocrine dysfunction
    • Screening for these diseases is not routine but required if suggested in the history and physical exam
  • Hyperthyroidism elevates LH and FSH, causes loss of mid-cycle LH peak leading to anovulation and low progesterone
  • Hypothyroidism causes menstrual irregularity, occasionally anovulation and rarely amenorrhea
  • Hypersecretion of growth hormone (GH) in acromegaly can lead to loss of fertility
  • Diabetes mellitus can reduce gonadotropin-releasing hormone (GnRH) and LH response which may lead to amenorrhea and oligomenorrhea
  • Adrenal disorders also interfere with normal reproductive function and can complicate pregnancy
    • Eg hyperandrogenism in congenital adrenal hyperplasia, decreased libido and amenorrhea in adrenal insufficiency, impaired LH response in Cushing’s syndrome
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.